Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cytek Biosciences, Inc. (CTKB)

Cytek Q2 revenue rises 6% to $48.1 million; net loss widens to $12.2 million

Mixed Impact 3 of 5 earnings Written later

Cytek Biosciences reported second-quarter 2026 revenue of $48.1 million, up 6% from a year earlier, and raised the midpoint of its full-year 2026 revenue guidance by $1 million. Net loss widened to $12.2 million from $5.6 million, driven by higher operating expenses, including a 24% rise in general and administrative expenses tied to litigation, severance and personnel costs.

Key points

  • Q2 2026 total revenue $48.1 million, up 6% from Q2 2025; gross profit $28.3 million, up 19%
  • Net loss $12.2 million in Q2 2026 versus $5.6 million in Q2 2025; operating expenses rose 15% to $39.7 million
  • Full-year 2026 total revenue guidance updated to $207 million to $212 million, midpoint raised by $1 million
  • Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026

The filing

CompanyCytek Biosciences, Inc. (CTKB)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:22 PM ET
Accession number0001193125-26-335212

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.